|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Physiology, University of Bergen, N-5009 Bergen, Norway; 2 School of Public Health, University of California, Berkeley, California 94720
| |
ABSTRACT |
|---|
|
|
|---|
Injury to soft tissue
results in the lowering of interstitial fluid pressure
(Pif), plasma protein extravasation, and increased total
tissue volume. In this study, the effects of N-acetyl
neurotensin(8-13) [AcNT(8-13)] on
Pif in rat trachea were examined after electrical stimulation (ES) of the vagus nerve. Pif was measured with
glass capillaries connected to a servocontrolled counterpressure
system. In pentobarbital-anesthetized female Wistar rats, the
Pif after intravenous saline was
1.8 ± 0.3 mmHg
(means ± SD) and decreased to
5.0 ± 0.6 mmHg
(P < 0.01, n = 9) after ES.
AcNT(8-13) (10 µg/kg) blocked the fall in
Pif after ES (
2.5 ± 2.3 mmHg, P < 0.01, n = 8). In tracheal tissue from animals
pretreated with AcNT(8-13) at the same dose and
immersed in phosphate-buffered saline (0.15 M, pH 7.4), the rate of
fluid accumulation in excised tissues was significantly reduced after
2 h. The ability of AcNT(8-13) to modulate the
fluid mechanics of tracheal interstitium after inflammation suggests
that it may be a useful tool for studying cell adhesion and related
factors that maintain structural integrity of connective tissue after injury.
peptide; anti-inflammatory effect; micropuncture; neurogenic inflammation
| |
INTRODUCTION |
|---|
|
|
|---|
NEUROTENSIN (NT), a 13-amino acid peptide, was first discovered and isolated from bovine hypothalami by Carraway and Leeman (3), who noticed that injections of purified fractions of hypothalamic extracts produced cutaneous vasodilation, hypotension, and cyanosis in anesthetized rats. It was then found that NT is widely expressed in the central nervous system and in peripheral tissues, where it may act as an endocrine or paracrine modulator of neural and smooth muscle function (11). Structure activity studies of NT have shown that much of the biological actions on smooth muscle and on binding to brain membrane fragments are conserved in the COOH-terminal hexapeptide of NT. For example, Granier et al. (9) showed that N-acetyl NT(8-13) [AcNT(8-13)] retained full binding property and pharmacological activity as tested by contraction of the guinea pig ileum. NT and some NT(8-13) analogs also have the unusual property of inhibiting the vascular leakage that occurs after traumatic injury to tissues. For example, in anesthetized rats, AcNT(8-13) inhibits edema formation after thermal injury to skin, after a knife cut to the abdominal muscle, and after freeze injury to the brain cortex (4, 5). AcNT(8-13) also reduced the fluid accumulation in the rat lung after intravenous injection of epinephrine (5).
Transcapillary fluid flux (Jv) is the product of
the capillary filtration coefficient (CFC), the hydrostatic pressure
(P), and the colloid osmotic pressure (COP) acting across the capillary wall (1). These parameters are interrelated in Eq. 1
|
(1) |
|
is the capillary reflection coefficient for proteins, and
P is the
net filtration pressure across the capillary wall. Pif is
one of the pressures that controls transcapillary fluid transport.
Transcapillary fluid flux is normally kept within narrow limits because
of "autoregulation" by Pif and COPif.
Increased fluid filtration and thereby increased interstitial volume
will raise Pif and reduce COPif. These changes will in turn normalize net filtration pressure and hence counteract further filtration. This balance is maintained in normal conditions but
undergoes rapid changes in acute inflammation. For example, thermal
injury to human skin is accompanied within minutes by increased
transvascular fluid flux and blister formation, yet the underlying
processes for this phenomenon are not well understood. In earlier
studies (13, 15), the egress of fluids into tissues during
inflammation was solely attributed to the release of mediators that
induced endothelial gap formation, thus increasing capillary permeability. Another mechanism identified in our laboratory is the
lowering of Pif. Pif is one of the pressures
participating in the control of transcapillary flux according to the
Starling hypothesis. Pif normally counteracts accumulation
of fluid in the tissue interstitium, but in the early phase of
inflammation it becomes a driving pressure for the increased transport
of fluid across the transcapillary wall and into the intestititum.
Therefore, in our experiments, Pif was measured after the
induction of circulatory arrest to avoid the accumulation of fluid in
the interstitial space that occurs after tissue injury with intact
circulation and thus allows registration of the lowering of
Pif as observed in the initial phase after an inflammatory
challenge. By using inflammation of tracheal tissue as experimental
model, it was shown that increased fluid flux can double interstitial
fluid volume within 10 min after initiation of the stimulus when the circulation is intact (12).
Studies from our laboratory (8, 24, 25) have demonstrated that electrical stimulation (ES) of the vagal nerve will lower Pif in the tracheal tissue. The normal slightly subatmospheric Pif becomes additionally negative after the onset of nerve stimulation, and this negativity accompanies the other signs of neurogenic inflammation, namely vasodilation, increased vascular permeability, and leakage of plasma protein, followed by accumulation of extracellular fluid, thus increasing the total tissue volume (14, 15). The lowering of Pif is the major hydrostatic pressure driving the rapid formation of edema that develops in this condition.
To characterize the factors that affect Pif, we examined
pharmacological agents that reduce inflammatory edema in experimental models of acute tissue injury. These agents include the
corticotropin-releasing hormone
-trinositol, mystixins, NT, and
dynorphin fragments (4, 7, 8, 21, 25). The aim of this
study was to determine whether the mechanism responsible for the
anti-inflammatory effect of AcNT(8-13) is linked to
changes in Pif. The effect of AcNT(8-13) on the lowering of Pif in the rat trachea after ES of the
vagal nerve was measured, as well as the effect of pretreatment with AcNT(8-13) on tissue imbibition of water in vitro.
Part of the present study has been presented briefly elsewhere
(6).
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Female Wistar rats (200-250 g) were obtained from M & B (Ry, Denmark) or from Harland (Oxon, UK). Food was available ad libitum. Animals were anesthetized with pentobarbital sodium [initial dose of 50 mg/kg body wt (bw) ip and supplemental doses were administered when required]. A branch of the femoral vein was cannulated for injection of AcNT(8-13) (0.1, 1, 3.1, 10, or 31 µg/kg bw), sodium nitroprusside, or saline (0.9% NaCl), or for the injection of the radiolabeled tracers. Circulatory arrest was induced with 0.5 ml of saturated KCl injected intravenously. All experimental protocols were approved by, and performed in accordance with, the recommendations of the Norwegian State Commission for Laboratory Animals.
Measurements
Interstitial fluid pressure. After the induction of circulatory arrest with saturated KCl, an extrathoracic portion of the trachea was exposed and the muscle lying over the trachea was split longitudinally. The left vagal nerve was dissected free from the carotid artery, at the same level as the exposed trachea, and placed on a stimulating electrode. The tracheal surface and the vagal nerve were covered with mineral oil to avoid desiccation. The time required for the experimental preparation was 3-5 min. Measurement of Pif was initiated thereafter and continued until 60 min after cardiac arrest. Pif was measured with a sharpened glass pipette (4-10 µm) penetrating the frontal portion of the tracheal tissue between the cartilage rings. The pipette tip was inserted into the tissue from the external layer of the adventitia via the submucosa and extended as deep as to the mucosal layer, with registration of pressures in the submucosa, which is the largest layer in the frontal portion of the trachea. We performed the measurements without opening the trachea. The glass capillary was connected to a servocontrolled counterpressure system (22, 23), and the counterpressure created by the servocontrolled pump (model 201, Ling Dynamic Systems; Royston, UK) was recorded with a pressure transducer (model 1280C, Hewlett-Packard) connected to an amplifier and recorder (Gould Instruments; Ballainvilliers, France). The glass pipettes were filled with 0.5 M NaCl colored with Evans blue dye to visualize the tip of the pipette. Micropuncture was performed under visual guidance with a microscope (model M3C, Wild; Heerbrugg, Switzerland), and care was taken to minimize stretch or compression at the site of puncture (23). The measurements were accepted when the following criteria were met: 1) no change of recorded pressure when increasing feedback gain; 2) suction applied by the servocontrolled pump gave increased electrical resistance in the pipette; verifying an open communication to interstitial fluid because of the lower tonicity of the fluid entering the pipette; and 3) the baseline measurements before and after Pif registration were unchanged. The last baseline measurement was performed in a plastic cup filled with saline placed at the level of the site of puncture. All surgical manipulations on or near the trachea were performed postmortem to avoid local inflammation that may increase interstitial fluid volume and confound accurate estimates of Pif.
Arterial pressure. Arterial blood pressure (Pa) was measured before and during administration of the test substance and until circulatory arrest was induced with saturated KCl as part of the experimental protocol for the measurement of Pif. Blood pressure was monitored by a cannula placed in the femoral artery and connected to a pressure transducer (model 840-22, Sensonor) and a recorder (Gould).
Electrical stimulation. ES was performed with a stimulator (model S60, Grass; Quincy, MA) with these parameters: 20 V, 20 Hz, and 0.5 ms for a total of 5 min.
In vitro swelling of tracheal tissues. The animals were treated as before, with cannulation of the femoral vein and intravenous injection of AcNT(8-13) (10 or 31 µg/kg bw) or saline. After cardiac arrest, the tracheas were dissected out, split longitudinally, and placed in preweighed vials that were then sealed and reweighed. Each vial, containing one trachea, was then filled with 5 ml of phosphate-buffered saline (PBS; 0.15 M adjusted to pH 7.4). After being soaked for 2, 4, 8, and 24 h, the tracheas were removed from the vials, the surface fluid was wiped gently with a paper towel, and they were then weighed. After being weighed, the sample was returned to the vial. After the last weighing (24 h), samples were dried at 65°C to obtain tissue dry weight. Total tissue water (TTW) was then calculated for each time interval assuming a constant dry weight during the 24 h of immersion.
Albumin extravasation and TTW.
Albumin extravasation (Ealb) and TTW were
measured as the 25-min distribution volume of 125I-labeled
human serum albumin (125I-HSA) and the accumulation of
tissue water during the same period of time, respectively. The
radiolabeled 125I-HSA (0.05 MBq) (Institute for Energy
Technique; Kjeller, Norway) was injected intravenously in 0.2 ml,
followed immediately by AcNT(8-13) (3.1, 10, or 31 µg/kg bw) or intravenous saline. The injection volume was 0.1 ml/100
g bw plus 0.2 ml saline to flush the cannula. In some experiments, the
vagus nerve was dissected free and stimulated 10 min after intravenous
injection of AcNT(8-13) or vehicle (see
Experimental Protocol). Five minutes before cardiac arrest
and 20 min after AcNT(8-13) injection, the rats
received an intravenous injection of 0.2 ml 131I-HSA (0.10 MBq) (Institute for Energy Technique; Kjeller, Norway). Blood samples
(0.5-1.0 ml) were taken by cardiac puncture just before cardiac
arrest. Samples of trachea were placed in preweighed vials, which were
sealed immediately and reweighed. The radioactivity in the plasma and
tissue samples was determined with a gamma counter (Wallac 1282, LKB;
Turku, Finland) with automatic spillover and background subtraction.
The samples were then dried at 65°C until a constant weight was
attained and water content [TTW, in ml/g dry weight (dw)] was
calculated as fresh weight (fw)
dw/dw
|
(2) |
|
(3) |
Solutions.
AcNT(8-13) (mol mass 859), provided by Phoenix
Pharmaceuticals (Belmont, CA) or by Bachem (Bubendorf, Switzerland),
was made up to stock solution of 100 µg/ml prepared by dissolving
AcNT(8-13) in 100 µl of 0.1 M acetic acid
subsequently diluted to the required concentration with 0.9% NaCl.
This solution or further dilutions with 0.9% NaCl were used for
intravenous injections of AcNT(8-13) at 0.1 ml/100 g
bw. Sodium nitroprusside (Merck) was made up to a solution of 100 µg/ml by dissolving the drug in 0.9% NaCl. The solution was used for
injection at 0.01 ml · min
1 · 100 g
bw
1 for a period of 10 min.
Experimental Protocol
Interstitial fluid pressure. AcNT(8-13) was administered intravenously at 0.1, 1, 3.1, 10, or 31 µg/kg bw, with the number of experiments equal to 8, 3, 4, 8, or 10 per dose, respectively. Cardiac arrest was induced 10 min after injection with intravenous saturated KCl at 0.5 to 1 ml, and measurement of Pif on the exposed trachea was commenced after the left vagal nerve was surgically isolated and placed in the electric stimulator. The time of circulation of the agent until induction of cardiac arrest is based on previous experiments (4). One or two recordings of Pif were obtained as control measurements, before sensory nerve stimulation. After nerve stimulation, repeated measurements of Pif were performed until 60 min after cardiac arrest. Two groups were used as controls, both groups consisting of vehicle-treated animals (0.1 ml/100 g bw 0.9% saline iv). The protocol for electrical nerve stimulation was used in the first group (n = 9) but not in the second group (n = 6). Finally, Pif was measured in sodium nitroprusside-treated rats (n = 4). Rats were given intravenous injections of sodium nitroprusside every 0.5 to 1 min for 10 min before cardiac arrest was induced. Measurement of Pif for this group and for the second control group was started immediately after exposure of the trachea and continued until 60 min after cardiac arrest.
In vitro swelling of tracheal tissues. The anesthetized animals were cannulated and pretreated with vehicle (n = 10) or AcNT(8-13) (10 or 31 µg/kg bw, n = 10), at an injection volume of 0.1 ml/100 g bw + 0.20 ml saline to flush the catheter. Cardiac arrest was induced 10 min later.
Ealb and TTW. The experiments were performed in two series with separate control groups and variable doses of AcNT(8-13). The first series consisted of three groups (n = 7 in each) pretreated either with AcNT(8-13) (3.1 or 10 µg/kg bw) or vehicle. The timing for the injection of the tracers was according to the following schedule: 0 min, 125I-HSA and AcNT(8-13)/vehicle; 20 min, 131I-HSA; 25 min, blood sample and KCl. This series was performed to investigate whether 3.1 µg/kg and 10 µg/kg had an effect on TTW and Ealb. The second series consisted of four groups pretreated with intravenous AcNT(8-13) (31 µg/kg bw) or vehicle and further subdivided by absence or presence of ES: vehicle-ES (n = 7); AcNT(8-13)-ES (n = 7); vehicle + ES (n = 8); AcNT(8-13) + ES (n = 8). The timing for the injection of the tracers and ES was according to the following schedule: 0 min, 125I-HSA and AcNT(8-13)/vehicle; 10 min, ES/-ES; 20 min, 131I-HSA; 25 min, blood sample and KCl. This series was performed to investigate whether the high TTW observed when tracheal tissue was allowed to swell was due to the high dose of AcNT(8-13) (31 µg/kg) and whether it had an effect on TTW and Ealb. Furthermore, we investigated whether this high dose was affecting the response to electrical nerve stimulation.
Statistical Analysis
Data on swelling were analyzed with one-way ANOVA at the different swelling times and subsequent Bonferroni and t-tests. Analysis of Pif and Ealb was performed using one-way ANOVA and subsequent Bonferroni and t-tests, with complementary use of the nonparametric test using Kruskal-Wallis one-way ANOVA on ranks with subsequent pairwise multiple comparison with Dunn's method when necessary. Values are presented as means ± SD, unless stated otherwise.| |
RESULTS |
|---|
|
|
|---|
Interstitial Fluid Pressure
Pif before ES (n = 9) was
1.8 ± 0.3 mmHg and decreased to
5.0 ± 0.6 mmHg (P < 0.05) after stimulation (Fig. 1),
which is in agreement with previous studies (24).
AcNT(8-13) did not affect the baseline
Pif, but it suppressed the lowering of Pif produced by ES. The attenuation was significant (P < 0.05) at 10 and 31 µg/kg bw iv, but not at 0.1, 1.0 nor 3.1 µg/kg
bw (Fig. 1). The wide standard deviation in the 10 µg/kg bw group is
due to one of eight animals that did not respond to
AcNT(8-13) (Fig. 1 vs. Fig.
2). Treatment with sodium nitroprusside
(Pif =
1.7 ± 0.3, n = 4),
which lowers Pa, did not induce a fall in Pif
compared with the control group (Pif =
1.8 ± 0.4, n = 6) at any time during the 60-min period of
measurements (Fig. 3).
|
|
|
Arterial Pressure
The effects of test substances on Pa are shown in Table 1. AcNT(8-13) at 0.1, 1.0, and 3.1 µg/kg bw induced a transient hypotensive effect, and Pa returned to preinjection levels within several minutes. AcNT(8-13) at 10 and 31 µg/kg bw induced a prolonged hypotensive response that lasted throughout the observation period. Injection of sodium nitroprusside induced a similar pattern of fall in Pa.
|
In Vitro Swelling of Tracheal Tissues
Samples of excised tracheal tissue immersed in PBS accumulate fluid (8). TTW increased significantly (P < 0.05) within the control group by comparing the fresh weight TTW (TTW at 0 h = 2.37 ± 0.08) to all other recording periods (TTW at 2 h = 3.02 ± 0.12; TTW at 4 h = 3.10 ± 0.11; TTW at 8 h = 3.04 ± 0.09; TTW at 24 h = 3.00 ± 0.11; values are means ± SE in ml/g dw). AcNT(8-13) at 10 and 31 µg/kg bw both prevented the increase of TTW in vitro. However, the mechanisms of action for the two doses appeared to be different. AcNT(8-13) at 10 µg/kg bw did not affect initial TTW, but it prevented the increase in TTW after soaking, showing a clear inhibitory effect on fluid accumulation at this dose after 2 h and compared with the control group. By contrast, the initial TTW of tracheal tissues from rats treated with AcNT(8-13) at 31 µg/kg bw were significantly higher, TTW at 0 h = 3.37 ± 0.09, and diminished after soaking, TTW at 2 h and TTW at 4 h (2.90 ± 0.05 and 2.93 ± 0.08, respectively). These results suggested that the peptide has a proinflammatory effect and had induced edema formation at the higher dose of 31 µg/kg bw; see Figs. 4 and 6.
|
Ealb and TTW
In the first series (Fig. 5) consisting of the three groups (each, n = 7) pretreated either with AcNT(8-13) at 3.1 µg/kg bw, 10 µg/kg bw or vehicle, there were no significant changes in TTW nor in the 25-min plasma space for the 125I-HSA. However, there was a significant increase in Ealb of AcNT(8-13) at the dose of 3.1 µg/kg bw, compared with the 10 µg/kg bw, but no changes when comparing the two groups with the vehicle-treated animals, making these results difficult to interpret. In the second series (Fig. 6), which consisted of the four groups treated in pairs either with intravenous AcNT(8-13) (31 µg/kg bw) or vehicle, and one group from each pair using the protocol for ES, there were significant differences for all three parameters (125I-HSA, TTW, and Ealb), except in the AcNT(8-13) (31 µg/kg bw) treatment for the two parameters 125I-HSA and Ealb compared with the control group. The 125I-HSA plasma space and the Ealb for the AcNT(8-13) at 31 µg/kg bw +ES were both significantly increased compared with the other three groups indicating an increased leakage. Furthermore, as shown previously (25), the values for both these parameters were significantly increased for the control group with ES compared with the control group without ES. The TTW was significantly (P < 0.05) increased for all groups compared with the control group without ES. The two groups treated with ES showed significantly higher values for TTW than the group treated with 31 µg/kg bw without ES, and there was no significant differences between these two groups treated with ES. The results showed the following: 1) pretreatment with 10 µg/kg bw AcNT(8-13) did not increase TTW or Ealb compared with the controls; 2) pretreatment with 31 µg/kg bw AcNT(8-13) increased TTW but did not increase Ealb; 3) pretreatment with AcNT(8-13) together with ES induced a large increase in protein leakage compared with all groups, thus indicating a synergistic effect of the two factors, AcNT(8-13) at 31 µg/kg and ES, on plasma leakage but not on tissue water because TTW was not additionally increased.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
In a previous study, we showed that AcNT(8-13) administered at 5-8 µg/kg bw intravenous to anesthetized rats 10 min before thermal injury to the paw, inhibited 65-75% of the volume of swelling that occurred 30 min later (5). The results here show that AcNT(8-13) inhibits the lowering of Pif, which develops during neurogenic inflammation in the trachea of rats. Pretreatment of the animals with AcNT(8-13) at 10 µg/kg bw also reduced the fluid accumulation of tissues placed in PBS, but at 31 µg/kg bw, AcNT(8-13) increased TTW and no imbibition of water occurred in vitro. The higher dose of AcNT(8-13) also potentiated TTW accumulation in the trachea both before and after ES of the vagus nerve because the values of water content in the tracheal tissue were markedly increased compared with both the vehicle-treated animals and the animals treated with AcNT(8-13) at 10 µg/kg. The highest dose of AcNT also induced a large increase in plasma albumin leakage when combined with the ES of the vagus nerve. These results provide a complex picture of how a peptide such as AcNT(8-13) modulates fluid dynamics in tissues during inflammation.
The ability of AcNT(8-13) at 10 µg/kg bw to
suppress the development of negative Pif during
inflammation provides an intuitive explanation of its actions in vivo
and in vitro. AcNT may act on cellular receptors that control the
tension of the extracellular matrix. A possible pathway would be the
stimulation of the
1-integrin receptor system, which
appears to be a common and final step involved in generating a lowering
of Pif because polyclonal and monoclonal antibodies to
1- and
2
1-integrins,
respectively, decreased Pif (18-20). Thus
we suggest that AcNT(8-13) acts via a cellular receptor, which in turn causes strengthening of the cytoskeleton, thus
stabilizing the
1-integrin function, but the exact
process by which AcNT(8-13) may affect
Pif and swelling via the integrin system and the
intracellular pathway is unclear.
AcNT(8-13) at 10 and 31 µg/kg bw produces hypotension. A change in Pa may reduce the transmural driving forces for fluid and protein egress from the microcirculation via an effect on capillary pressure (Pc), as described in Eq. 1, and thereby may also affect Pif. ES of the vagus nerve also changes Pa, but this effect is not of interest in the current experiments because ES was imposed after cardiac arrest. Several facts, however, suggest that the effect of AcNT(8-13) on Pif is not determined by changes in Pa. First, Pif measurements after AcNT(8-13) and before nerve stimulation are the same as in the vehicle-treated animals, i.e., slightly subatmospheric. Second, we showed that lowering of Pa with sodium nitroprusside over a 60-min period did not have effects on Pif. Thus we conclude that the effects produced by AcNT(8-13) on Pif are not secondary to a fall in Pa.
We (8) have previously shown that tracheas from rats
pretreated with the synthetic peptide mystixin-7 (20 µg/kg bw)
reduced the swelling rate of the tracheal tissue placed in PBS. On the basis of this finding, we performed similar experiments with the two
doses of AcNT(8-13) that inhibited the lowering of
Pif, namely at doses of 10 and 31 µg/kg. Pretreatment
with the lowest dose reduced the swelling, measured as a lower content
of TTW, after 2 h of imbibition, compared with the vehicle-treated
tissues and the water content in the tissue before the immersion in PBS
was not increased. In contrast, the treatment with
AcNT(8-13) at a dose of 31 µg/kg induced a large
increase in TTW, indicating a proinflammatory effect of
AcNT(8-13) at this dose. The increase in water
preload was unexpected and so large that when the trachea was placed in
the PBS solution the tissues in fact had a reduction in TTW content.
There is no evidence that the tissue osmotic pressure was hypotonic
compared with the PBS solution because the latter does not contain
proteins. The observed preload could be explained by changes in the
mechanical properties of the interstitial tissue in balancing the
constraining force of the tissue, fibers and connective tissue cells,
and the expanding forces (glycosaminoglycans). The water preload of 31 µg/kg bw may be sufficient to attenuate the generation of negative
Pif during inflammation. The proinflammatory effect was not
seen at lower doses of AcNT(8-13). Furthermore, the
experiment with soaking of the tracheal tissue did not include the
electrical nerve stimulation. Nevertheless,
AcNT(8-13) inhibited the rate of swelling, indicating
that this peptide could not exert its inhibitory effect by affecting
the release of sensory neuropeptides. In light of this and in
combination with the role of the
1-integrin in
controlling the tension of the extracellular matrix, there appears to
be indications that the inhibitory effects of
AcNT(8-13), both on lowering of Pif and
swelling rate, are mediated via mechanisms which improve binding of the
structures in the extracellular matrix.
We performed two series of experiments using the radiolabeled tracer technique measuring the 125I-HSA, TTW, and Ealb at different doses of AcNT(8-13). The first series simply looked at these parameters following pretreatment with doses of 3.1 and 10 µg/kg bw compared with the vehicle-treated ones, to confirm that AcNT(8-13) at these doses did not increase plasma protein leakage or content of tissue water. The results clearly indicate that none of these treatments led to changes compared with the control group, except for the surprising observation that the plasma protein leakage measured as the 5-min albumin space, Ealb, was significantly reduced in the 3.1 µg/kg bw dose compared with the 10 µg/kg bw dose. The findings suggest that compared with the controls, AcNT(8-13) at the doses used here has no proinflammatory effect.
In the second series of experiments we used the radiolabeled tracer technique measuring the 125I-HSA, TTW, and Ealb, and pretreatment with AcNT(8-13) at 31 µg/kg alone or in combination with ES of vagus nerve. The treatment with AcNT(8-13) at 31 µg/kg alone induced a significant increase in TTW as observed in the swelling experiments, but this treatment is not followed by increased protein leakage. The combination of the two treatments, 31 µg/kg AcNT(8-13) and ES of the vagus nerve, also induced an increase in TTW with responses comparable with the two other treatments alone and significantly increased compared with the vehicle-treated group. However, the protein leakage was increased threefold compared with the group with ES of the vagus nerve, thus demonstrating a synergistic response to protein extravasation for the combination of two treatments. The neurogenic inflammation response induced by ES releasing sensory neuropeptides is known to give increased protein leakage mainly created by the formation of gaps between the endothelial cells of the postcapillary venules by the neuropeptide substance P (15). Gully et al. (10) showed that the release of histamine is prevented by a selective NT receptor antagonist. This indicates that activation of this receptor by AcNT(8-13) could induce mast cell activation. It is therefore possible that the highest dose of AcNT(8-13), 31 µg/kg, is able to induce protein extravasation via mast cell activation while the lower doses of the peptide are not able to induce the same response. It is known that NT and NT fragments at higher doses release inflammatory mediators from mast cells (3, 10) and such release may contribute to the proinflammatory effect seen at AcNT(8-13) at 31 µg/kg bw. It should be noted, however, that AcNT(8-13) inhibits vascular leakage from blood vessels of the brain cortex and lung alveoli, tissues insensitive to inflammatory mediators such as histamine and bradykinin (5). Furthermore, we (8) observed a similar dose-dependent response in a recent study with the use of synthetic peptide mystixin-7. Unpublished observations (H. Strukova and E. T. Wei) indicate that the mystixin-7 peptide induced release of histamine from isolated rat peritoneal mast cells in vitro at doses of 0.1 µM. These observations may indicate that variable response to these peptides is based on a dose-dependent response to release of histamine from local mast cells. It is also known that some substances can induce both pro- and anti-inflammatory reactions depending on the route of administration (16), tissue, or species (2, 17). With the radiolabeled tracer technique, the proinflammatory effects were not observed at 10 µg/kg iv, a dose that inhibits lowering of Pif after nerve stimulation. At this lower dose, the ability of AcNT(8-13) to inhibit tissue imbibition of water, as measured by tissue weights, was also demonstrated.
Compliance, the relationship between the changes in the two parameters,
interstitial fluid volume (IFV) and Pif, is important for
the control of tissue fluid because it determines the level of
counterpressure exerted by Pif concomitant with the
increase in IFV. A proper determination of compliance requires a set of corresponding Pif and interstitial volume measurements. A
change in tissue compliance can be measured if two different data sets have a clearly different relationship between these two parameters. Alternatively, if one parameter is constant whereas the other one
changes, which is the case when Pif is lowered after vagal nerve stimulation when circulation is arrested, these must clearly be a
change in the interstitial volume-pressure relationship but not
necessarily the compliance (i.e., IFV/
Pif). Our
conclusion is that Pif is dependent on compliance, but more
so under the present protocol, the acute changes are not a passive
effect due to the relationship between Pif and IFV but
rather the effect of AcNT on stabilizing the interstitial matrix. Thus
the present data are conclusive in this regard and that determination
of compliance after AcNT will not alter this conclusion.
The pathophysiological processes that underlie vascular leakage in acute inflammation remain a relatively unexplored topic in research. The interactions between pharmacological agents that suppress vascular leakage and affect Pif are now, however, better defined and may provide tools for further investigation of the molecular mechanisms in tissue stroma that generate the negative Pif.
In summary, we have characterized the actions of AcNT(8-13) on the physical forces that generate edema in the acute phase of inflammation. The receptive mechanisms of this peptide in the extracellular matrix may allow a more accurate description of the targets and cellular receptors that influences Pif and control edema formation.
| |
ACKNOWLEDGEMENTS |
|---|
The authors acknowledge the technical assistance of Gerd Signe Salvesen and Eli Gunn Kjørlaug.
| |
FOOTNOTES |
|---|
This study was supported by the Norwegian Research Council, Norwegian Heart Association.
Address for reprint requests and other correspondence: E.-A. B. Gjerde, Dept. of Physiology, Univ. of Bergen, Arstadveien 19, N-5009 Bergen, Norway (E-mail: eli-anne.gjerde{at}fys.uib.no).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
May 9, 2002;10.1152/ajpheart.00086.2002
Received 2 February 2002; accepted in final form 2 May 2002.
| |
REFERENCES |
|---|
|
|
|---|
1.
Aukland, K,
and
Reed RK.
Interstitial-lymphatic mechanisms in the control of extracellular fluid volume.
Physiol Rev
73:
1-78,
1993
2.
Brain, SD,
and
Williams TJ.
Neuropharmacology of peptides in skin.
Semin Dermatol
7:
278-283,
1988[Web of Science][Medline].
3.
Carraway, R,
and
Leeman SE.
The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami.
J Biol Chem
248:
6854-6861,
1973
4.
Gao, GC,
and
Wei ET.
Potencies of various neurotensin-(8-13) analogs for inhibition of heat-induced edema in the anesthetized rat.
Regul Pept
56:
41-48,
1995[Web of Science][Medline].
5.
Gao, GC,
and
Wei ET.
Xenopsin, neurotensin, neurotensin(8-13) and N-acetyl-neurotensin(8-13) inhibit vascular leakage in rats after tissue injury.
J Pharmacol Exp Ther
265:
619-625,
1993
6.
Gjerde, EA,
Reed RK,
and
Wei ET.
Acetyl-neurotensin(8-13) abolishes increased negativity of interstitial fluid pressure (PIF) in neurogenic inflammation (Abstract).
FASEB J
12, Suppl:
A186,
1998.
7.
Gjerde, EA,
Woie K,
Wei ET,
and
Reed RK.
Corticotropin-releasing hormone inhibits lowering of interstitial pressure in rat trachea after neurogenic inflammation.
Eur J Pharmacol
352:
99-102,
1998[Web of Science][Medline].
8.
Gjerde, EA,
Woie K,
Wei ET,
and
Reed RK.
Lowering of interstitial fluid pressure after neurogenic inflammation is inhibited by mystixin-7 peptide.
Am J Physiol Heart Circ Physiol
279:
H1377-H1382,
2000
9.
Granier, C,
van Rietschoten J,
Kitabgi P,
Poustis C,
and
Freychet P.
Synthesis and characterization of neurotensin analogues for structure/activity relationship studies. Acetyl-neurotensin-(8-13) is the shortest analogue with full binding and pharmacological activities.
Eur J Biochem
124:
117-124,
1982[Web of Science][Medline].
10.
Gully, D,
Lespy L,
Canton M,
Rostene W,
Kitabgi P,
Le Fur G,
and
Maffrand JP.
Effect of the neurotensin receptor antagonist SR48692 on rat blood pressure modulation by neurotensin.
Life Sci
58:
665-674,
1996[Web of Science][Medline].
11.
Kitabgi, P.
Effects of neurotensin on intestinal smooth muscle: application to the study of structure-activity relationships.
Ann NY Acad Sci
400:
37-55,
1982[Web of Science][Medline].
12.
Koller, ME,
and
Reed RK.
Increased negativity of interstitial fluid pressure in rat trachea in dextran anaphylaxis.
J Appl Physiol
72:
53-57,
1992
13.
Korthuis, RJ,
Wang CY,
and
Spielman WS.
Transient effects of histamine on the capillary filtration coefficient.
Microvasc Res
28:
322-344,
1984[Web of Science][Medline].
14.
Lundberg, JM,
and
Saria A.
Capsaicin-sensitive vagal neurons involved in control of vascular permeability in rat trachea.
Acta Physiol Scand
115:
521-523,
1982[Web of Science][Medline].
15.
McDonald, DM.
Endothelial gaps and permeability of venules in rat tracheas exposed to inflammatory stimuli.
Am J Physiol Lung Cell Mol Physiol
266:
L61-L83,
1994
16.
Rampart, M,
and
Williams TJ.
Polymorphonuclear leukocyte-dependent plasma leakage in the rabbit skin is enhanced or inhibited by prostacyclin, depending on the route of administration.
Am J Pathol
124:
66-73,
1986[Abstract].
17.
Raud, J,
Lundeberg T,
Brodda-Jansen G,
Theodorsson E,
and
Hedqvist P.
Potent anti-inflammatory action of calcitonin gene-related peptide.
Biochem Biophys Res Commun
180:
1429-1435,
1991[Web of Science][Medline].
18.
Reed, RK,
Rubin K,
Wiig H,
and
Rodt SA.
Blockade of beta 1-integrins in skin causes edema through lowering of interstitial fluid pressure.
Circ Res
71:
978-983,
1992
19.
Rodt, SA,
Ahlen K,
Berg A,
Rubin K,
and
Reed RK.
A novel physiological function for platelet-derived growth factor-BB in rat dermis.
J Physiol
495:
193-200,
1996
20.
Rodt, SA,
Reed RK,
Ljungström M,
Gustafsson TO,
and
Rubin K.
The anti-inflammatory agent alpha-trinositol exerts its edema- preventing effects through modulation of beta 1 integrin function.
Circ Res
75:
942-948,
1994
21.
Wei, ET,
Thomas HA,
Gjerde EA,
Reed RK,
Burov SV,
Korolkov VI,
Glynskaya OV,
Dorosh MY,
and
Vlasov GP.
Dynorphin A(6-12) analogs suppress thermal edema.
Peptides
19:
767-775,
1998[Web of Science][Medline].
22.
Wiederhielm, CA,
Woodbury JW,
Kirk S,
and
Rushmer RF.
Pulsatile pressures in the microcirculation of frog's mesentery.
Am J Physiol
207:
173-176,
1964
23.
Wiig, H,
Reed RK,
and
Aukland K.
Micropuncture measurement of interstitial fluid pressure in rat subcutis and skeletal muscle: comparison to wick-in-needle technique.
Microvasc Res
21:
308-319,
1981[Web of Science][Medline].
24.
Woie, K,
Koller ME,
Heyeraas KJ,
and
Reed RK.
Neurogenic inflammation in rat trachea is accompanied by increased negativity of interstitial fluid pressure.
Circ Res
73:
839-845,
1993
25.
Woie, K,
and
Reed RK.
Neurogenic inflammation and lowering of interstitial fluid pressure in rat trachea is inhibited by alpha-trinositol.
Am J Respir Crit Care Med
150:
924-928,
1994[Abstract].
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |